New drug combo shows promise for shrinking stomach tumors before surgery
NCT ID NCT06693128
First seen Jan 28, 2026 · Last updated May 22, 2026 · Updated 16 times
Summary
This study tests whether adding two drugs (camrelizumab and apatinib) to standard chemotherapy before surgery can help shrink tumors in people with advanced stomach or gastroesophageal junction cancer. About 80 participants will receive the treatment before their planned surgery. The main goal is to see how many patients have no cancer cells left in the tumor after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Changhai Hospital
Shanghai, China
-
Sichuan Cancer Hospital & Institute
Chengdu, China
-
Yantai Yuhuangding Hospital
Yantai, China
Conditions
Explore the condition pages connected to this study.